About: Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $27.28 (+1.56%)
VKTX NASDAQ Viking Therapeutics Inc
Viking Therapeutics Inc share price
VKTX price activity
Last Price
$27.280
Change (24hr)
0.42 USD (1.56%)
Volume
5.08M
Volume (4w avg)
-
Open
$26.77
Day Range
$26.31 - $27.83
Previous Close
$26.86
Last Trade
30 Oct, 8:17 pm GMT+0
Delayed
30 Oct, 8:17 pm GMT+0
VKTX price performance
Delayed
30 Oct, 8:17 pm GMT+0
VKTX Market Signals